Evidence map›Paper›PMID 25105115›Full record

ArticleFrontiers in chemistry2014

Bis-indole derivatives with antitumor activity turn out to be specific ligands of human telomeric G-quadruplex.

Jussara Amato, Nunzia Iaccarino, Bruno Pagano, Rita Morigi, Alessandra Locatelli, Alberto Leoni, Mirella Rambaldi, Pasquale Zizza, Annamaria Biroccio, Ettore Novellino and 1 more

Abstract read
In one paragraph

Article in Frontiers in chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jussara AmatoDepartment of Pharmacy, University of Naples "Federico II" Naples, Italy.
Nunzia IaccarinoDepartment of Pharmacy, University of Naples "Federico II" Naples, Italy.
Bruno PaganoDepartment of Pharmacy, University of Naples "Federico II" Naples, Italy.
Rita MorigiDepartment of Pharmacy and Biotechnology (FaBiT), University of Bologna Bologna, Italy.
Alessandra LocatelliDepartment of Pharmacy and Biotechnology (FaBiT), University of Bologna Bologna, Italy.
Alberto LeoniDepartment of Pharmacy and Biotechnology (FaBiT), University of Bologna Bologna, Italy.
Mirella RambaldiDepartment of Pharmacy and Biotechnology (FaBiT), University of Bologna Bologna, Italy.
Pasquale ZizzaExperimental Chemotherapy Laboratory, Regina Elena National Cancer Institute Rome, Italy.
Annamaria BiroccioExperimental Chemotherapy Laboratory, Regina Elena National Cancer Institute Rome, Italy.
Ettore NovellinoDepartment of Pharmacy, University of Naples "Federico II" Naples, Italy.
Antonio RandazzoDepartment of Pharmacy, University of Naples "Federico II" Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bis-indolinone derivatives having either 2,6-disubstituted pyridine core (1a and 1b) or 1,10-disubstituted phenanthroline core (2a and 2b), already known to have antitumor activity, have been tested as potential G-quadruplex binders. Compounds 2a and 2b are able to selectively stabilize G-quadruplex over duplex DNA, and also to discriminate among different G-quadruplex structures, having a particular affinity for the parallel form of the human telomeric G-quadruplex. Both compounds are also able to induce telomeric DNA damage that may explain the activity of these compounds.

Indexed as

anticancer activityG-quadruplexphenanthroline derivativespyridine derivativestelomeric damagethermal stabilization

Identifiers

PMID25105115
PMCPMC4109613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.